The once-daily tablet also cut weight about 4% versus placebo at 13 weeks, with no dropouts from stomach side effects, the company says. Obesity phase 3 data is due in 2028.
Recap by typeshit. Full story at Yahoo Finance.
The candidate blocks a signal behind appetite loss and high energy burn in cancer cachexia, where patients waste away even while eating.
The new preprint looks at whether symptom relief people report on GLP-1 medications comes from weight loss alone or something else.
Lilly says participants lost 44 to 47 pounds versus about 21 on Ozempic, with bigger A1C drops. It plans to file for approval in 2027.
Lilly reports people on retatrutide lost 44 to 47 pounds over 80 weeks versus about 21 on Ozempic. It plans to file for approval in 2027.
Post hoc REDEFINE 1 data shown at The Menopause Society meeting found Novo's combo worked before, during and after menopause, with Mayo's Maria Hurtado Andrade urging caution.
University of Pretoria researchers found the 16-amino-acid peptide hit all 12 strains tested with low toxicity to mammalian cells. Wound stability is the next big hurdle.
Loading…